-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pembrolizumab showed efficacy against PD-L1-positive (combined positive score (CPS)≥1) gastric/gastroesophageal junction (G/GEJ) cancer in the first-, second- and third-line environments of the KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059 trials, respectively.
to better describe the specificity of CPS as a clinical prognostic predictor, the researchers further analyzed the efficacy of Pym monoantia in patients who ≥ CPS≥10.
this analysis includes KEYNOTE-059 queue 1 (Pim monoantial, n-46; after-the-fact analysis), KEYNOTE-061 (Pim monoantial, n-53; chemotherapy, n-55; post-analysis) and KEYNOTE-062 (Pim monoantial, n92; Cancer patients with CPS≥10 in the KEYNOTE-059 queue 1 (Pembrolizumab, 46;), KEYNOTE-061 (Pembrolizumab, s 53; chemotherapy, s.55;) trial.
efficacy prognosis includes total lifetime (OS), progress-free lifetime (PFS), objective response rate (ORR), and reaction duration (DOR).
follow-up time for patients with the KEYNOTE-059 trial was 6 months, with the medium OS being 8 months (95% CI 5.8 to 11.1), or 17% orR, and the medium DOR being 21 months (3 to 35 plus).
patients with the KEYNOTE-061 trial had a prognosis of 9 months in the KEYNOTE-061 trial, and the medium OS in the Pym monoantial and chemotherapy groups was 10 months vs 8 months (HR 0.64; 95% CI 0.41 to 1.0) respectively. 2), the medium PFS is 3 months (HR 0.86; 95% CI 0.56 to 1.33), ORR is 25% vs 9%, the middle DOR (range) is not reached (4 to 26) vs 7 months (3 to 7).
patients in the KEYNOTE-062 trial had a prognosis of 11 months in KEYNOTE-062, and the middle OS in the Pym monoantial and chemotherapy groups was 17 months vs 11 months (HR 0.69; 95% CI 0.49 to 0.97), and the middle was PFS is 3 months vs 6 months (HR 1.09, 95% CI 0.79 to 1.49), ORR is 25% vs 38%, and the middle DOR (range) is 19 months (1 to 34 plus) vs 7 months (2 to 30 plus).
comprehensive analysis showed that both Pym monotherapy treated G/GEJ cancer patients with CPS≥10 as a several-line therapy showed consistent beneficial results, resulting in a more favorable clinical prognosis.
